Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By Sue Sutter

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.

Climbing a mountain
Novo and Lilly are making progress in their uphill battle against ads for compounded GLP-1 products. (Shutterstock)

More from Marketing & Advertising

More from Compliance